Pharmaceutical compositions and methods for treating age-related macular degeneration with melatonin analogues

• US 8,785,491 B2
• Filed: 06/17/2009
• Issued: 07/22/2014
• Est. Priority Date: 06/19/2008
• Status: Expired due to Fees

• Current Assignee: Takeda Pharmaceutical Company Limited
• Original Assignee: Takeda Pharmaceuticals USA Incorporated (Takeda Pharmaceutical Company Limited)
• Inventors: Baron, David, Hirai, Keisuke, Shintani, Yasushi, Uchikawa, Osamu
• Primary Examiner(s): Draper, Leslie A. Royds
• Application Number:
  US13/063,672
• Publication Number:
  US 20110229464A1
• Time in Patent Office: 1,861 Days
• US Class Current: 514/468
• CPC Class Codes: A61K 31/343 condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• CPC Class Codes: A61K 41/0057 Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61N 5/062 Photodynamic therapy, i.e. excitation of an agent
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: C07D 307/93 condensed with a ring other than six-membered

Abstract

Pharmaceutical compositions and methods for treating and/or preventing age-related macular degeneration with melatonin analogues are provided.

Claims

1. A method for treating age-related macular degeneration in a patient in need thereof, wherein said method comprises identifying a patient in need of treatment for age-related macular degeneration, and administering (S)—

N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]propionamide to said patient.

2. The method of claim 1, wherein the patient is identified by visual examination of the patient.

3. The method of claim 1, wherein said age-related macular degeneration is the dry form.

4. The method of claim 1, wherein said age-related macular degeneration is the wet form.

5. The method of claim 1, wherein said age-related macular degeneration occurs in one eye.

6. The method of claim 1, wherein said age-related macular degeneration occurs in two eyes.

7. The method of claim 1, wherein said administration of (S)—

N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno [5,4-b]furan-8-yl]ethyl]propionamide is by an oral dosage form.

8. The method of claim 1, wherein said administration of (S)—

N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno [5,4-b]furan-8-yl]ethyl]propionamide is by an injectable dosage form.

9. The method of claim 1, wherein said administration of (S)—

N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno [5,4-b]furan-8-yl]ethyl]propionamide is by a skin-patch dosage form.

10. The method of claim 1, wherein said administration of (S)—

N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno [5,4-b]furan-8-yl]ethyl]propionamide is by a liquid, powder, ointment, paste, gel or cream dosage form.

11. The method of claim 1, wherein said (S)—

N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]propionamide is administered in a dose of from 1 mg to 1000 mg.

12. The method of claim 1, wherein said (S)—

N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno [5,4-b]furan-8-yl]ethyl]propionamide, is administered in a dose of from 1 mg to 1000 mg.

13. The method of claim 1, wherein said (S)—

N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]propionamide is administered in a dose once daily.

14. The method of claim 13, wherein said (S)—

N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]propionamide is administered in the evening.

15. The method of claim 13, wherein said (S)—

N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]propionamide is administered prior to sleep.

16. The method of claim 1, wherein said (S)—

N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]propionamide is administered in a dose twice daily.

17. The method of claim 1, wherein said (S)—

N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]propionamide is administered in a dose more than twice daily.

18. The method of claim 1, further comprising administering photodynamic therapy.

19. The method of claim 1, further comprising administering therapeutic amount of a pharmaceutical agent selected from the group consisting of bevacizumab, ranibizumab, melatonin, pegatanib, and combinations thereof.

20. A method for treating age-related macular degeneration in a patient in need thereof, wherein said method comprises administering (S)—

N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]propionamide to said patient.

21. The method of claim 20, wherein said (S)N-[2-[4 hydroxy-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]propionamide administered in a dose of from 1 mg to 1000 mg.

22. The method of claim 20 further comprising administering photodynamic therapy.

23. The method of claim 20, further comprising administering therapeutic amount of a pharmaceutical agent selected from the group consisting of bevacizumab, ranibizumab, melatonin, pegatanib, and combinations thereof.